title: Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase.
authors.forename: M
authors.initials: M
authors.lastname: Sonmez
authors.forename: E
authors.initials: E
authors.lastname: Ovali
authors.forename: S B
authors.initials: SB
authors.lastname: Omay
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016903:Drug Monitoring; D006801:Humans; D015465:Leukemia, Myeloid, Accelerated Phase / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D015275:Tumor Lysis Syndrome / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; C498826:nilotinib